Hui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hui Zhang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Bing Zhang
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA
1 shared publication - Bolin Chen
School of Computer Science, Northwestern Polytechnical University, Xi’an 710072, China
1 shared publication - Chen Huang
Department of Genetics and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
1 shared publication Clinical Proteomic Tumor Analysis Consortium Investigators
1 shared publication- Daniel Cui Zhou
Oncology Division, Department of Medicine, Washington University in St. Louis, St. Louis, USA
1 shared publication - Daniel W. Chan
Johns Hopkins University, Baltimore, MD
1 shared publication
Latest Publications
- Open Access
- 18 March 2024
- Published by Elsevier in Lung Cancer
- Vol. 191, 107538
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
- 18 March 2024
- Published by Elsevier in Lung Cancer
- Vol. 191, 107538
Open AccessAnlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
- 1 July 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (13_Supplem) , 17
Abstract 17: Proteogenomic characterization of pancreatic ductal adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive cancer with 5-year survival rate less than 10%. Although numerous efforts have been made to characterize the functional driver genes of PDAC, the impacts of genomic alterations on protein modifications and molecular mechanism of this cancer type are still not well defined. To this end, Investigators from The Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted the first comprehensive characterization of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues using whole genome sequencing, whole exome sequencing, methylation, RNA-seq, miRNA-seq, proteomics, phosphoproteomics, and glycoproteomics. To address the inherent low neoplastic cellularity of pancreatic cancer, multiple orthogonal strategies using molecular features and histology imaging were deployed to deconvolute the cellularity and identify 105 tumors with sufficient neoplastic purity for downstream analyses. Proteomics, phosphoproteomics, and glycoproteomics analyses by mass spectrometry identified and quantified 11,662 proteins, 51,469 phosphosites, and 34,024 glycopeptides, respectively. Genomic data revealed that 97% of the cancers harbored KRAS alterations in our cohort. In addition, we found that somatic mutations and copy number alterations could impact gene and protein expression, as well as protein modifications such as phosphorylation and glycosylation. Glycoproteomic analyses uncovered tumor-associated alterations in glycoprotein biosynthesis and glycoproteins as potential targets for diagnosis or therapeutic intervention. Over-expressed kinase substrates and their corresponding kinases were identified with integration of global proteomic and phosphoproteomic measurements, thus identifying potential therapeutic targets. The results of our molecular and cellular subtyping revealed a small group of immune-hot subtype tumors that could benefit from immunotherapy, as well as the underlying mechanisms associated with major groups of immune-cold subtypes, including endothelial cell remodeling, glycolysis, and cell junction dysregulation. Non-negative matrix factorization (NMF)-based proteogenomics subtyping revealed two clusters with strong prognostic relevance. Finally, we identified proteins and glycoproteins overexpressed in early stage pancreatic cancer that may serve as candidates for early detection. This comprehensive proteogenomic characterization of PDAC provides a valuable resource for uncovering the molecular mechanisms of this cancer and thus paves the way for discovery of novel early detection and therapeutic targets. Citation Format: Liwei Cao, Chen Huang, Daniel Cui Zhou, Oliver F. Bathe, Daniel W. Chan, Ralph H. Hruban, Li Ding, Bing Zhang, Hui Zhang, Clinical Proteomic Tumor Analysis Consortium Investigators. Proteogenomic characterization of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 17.
- 1 July 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (13_Supplem) , 17
Abstract 17: Proteogenomic characterization of pancreatic ductal adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive cancer with 5-year survival rate less than 10%. Although numerous efforts have been made to characterize the functional driver genes of PDAC, the impacts of genomic alterations on protein modifications and molecular mechanism of this cancer type are still not well defined. To this end, Investigators from The Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted the first comprehensive characterization of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues using whole genome sequencing, whole exome sequencing, methylation, RNA-seq, miRNA-seq, proteomics, phosphoproteomics, and glycoproteomics. To address the inherent low neoplastic cellularity of pancreatic cancer, multiple orthogonal strategies using molecular features and histology imaging were deployed to deconvolute the cellularity and identify 105 tumors with sufficient neoplastic purity for downstream analyses. Proteomics, phosphoproteomics, and glycoproteomics analyses by mass spectrometry identified and quantified 11,662 proteins, 51,469 phosphosites, and 34,024 glycopeptides, respectively. Genomic data revealed that 97% of the cancers harbored KRAS alterations in our cohort. In addition, we found that somatic mutations and copy number alterations could impact gene and protein expression, as well as protein modifications such as phosphorylation and glycosylation. Glycoproteomic analyses uncovered tumor-associated alterations in glycoprotein biosynthesis and glycoproteins as potential targets for diagnosis or therapeutic intervention. Over-expressed kinase substrates and their corresponding kinases were identified with integration of global proteomic and phosphoproteomic measurements, thus identifying potential therapeutic targets. The results of our molecular and cellular subtyping revealed a small group of immune-hot subtype tumors that could benefit from immunotherapy, as well as the underlying mechanisms associated with major groups of immune-cold subtypes, including endothelial cell remodeling, glycolysis, and cell junction dysregulation. Non-negative matrix factorization (NMF)-based proteogenomics subtyping revealed two clusters with strong prognostic relevance. Finally, we identified proteins and glycoproteins overexpressed in early stage pancreatic cancer that may serve as candidates for early detection. This comprehensive proteogenomic characterization of PDAC provides a valuable resource for uncovering the molecular mechanisms of this cancer and thus paves the way for discovery of novel early detection and therapeutic targets. Citation Format: Liwei Cao, Chen Huang, Daniel Cui Zhou, Oliver F. Bathe, Daniel W. Chan, Ralph H. Hruban, Li Ding, Bing Zhang, Hui Zhang, Clinical Proteomic Tumor Analysis Consortium Investigators. Proteogenomic characterization of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 17.
- 7 October 2014
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 71 (2) , 749-755
Erythropoietin (EPO) Protects Against High Glucose-Induced Apoptosis in Retinal Ganglional Cells
The aim of this study was to investigate the protective effect and mechanism of EPO on the apoptosis induced by high levels of glucose in retinal ganglial cells (RGCs). High glucose-induced apoptosis model was established in RGCs isolated from SD rats (1–3 days old) and identified with Thy1.1 mAb and MAP-2 pAb. The apoptosis was determined by Hochest assay. The levels of ROS were quantitated by staining the cells with dichloro-dihydro-fluorescein diacetate (DCFH-DA) and measure by flow cytometry. The SOD, GSH-Px, CAT activities, and levels of T-AOC and MDA were determined by ELISA. Change in mitochondrial membrane potential (Δψm) was also assessed by flow cytometry, and expressions of Bcl-2, Bax, caspase-3, caspase-9, and cytochrome C were assessed by western blotting. The RGCs treated with high glucose levels exhibited significantly increased apoptotic rate and concentrations of ROS and MDA. Pretreatment of the cells with EPO caused a significant blockade of the high glucose-induced increase in ROS and MDA levels and apoptotic rate. EPO also increased the activities of SOD, GSH-Px, and CAT, and recovered the levels of T-AOC levels. As a consequence, the mitochondrial membrane potential was improved and Cyt c release into the cytoplasm was prevented which led to significantly suppressed up-regulation of Bax reducing the Bax/Bcl-2 ratio. The expressions of caspase-3 and caspase-9 induced by high glucose exposure were also ameliorated in the RGCs treated with EPO. The protective effect of EPO against apoptosis was mediated through its antioxidant action. Thus, it blocked the generation of pro-apoptotic proteins and apoptotic degeneration of the RGCs by preventing the mitochondrial damage.
- 7 October 2014
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 71 (2) , 749-755
Erythropoietin (EPO) Protects Against High Glucose-Induced Apoptosis in Retinal Ganglional Cells
The aim of this study was to investigate the protective effect and mechanism of EPO on the apoptosis induced by high levels of glucose in retinal ganglial cells (RGCs). High glucose-induced apoptosis model was established in RGCs isolated from SD rats (1–3 days old) and identified with Thy1.1 mAb and MAP-2 pAb. The apoptosis was determined by Hochest assay. The levels of ROS were quantitated by staining the cells with dichloro-dihydro-fluorescein diacetate (DCFH-DA) and measure by flow cytometry. The SOD, GSH-Px, CAT activities, and levels of T-AOC and MDA were determined by ELISA. Change in mitochondrial membrane potential (Δψm) was also assessed by flow cytometry, and expressions of Bcl-2, Bax, caspase-3, caspase-9, and cytochrome C were assessed by western blotting. The RGCs treated with high glucose levels exhibited significantly increased apoptotic rate and concentrations of ROS and MDA. Pretreatment of the cells with EPO caused a significant blockade of the high glucose-induced increase in ROS and MDA levels and apoptotic rate. EPO also increased the activities of SOD, GSH-Px, and CAT, and recovered the levels of T-AOC levels. As a consequence, the mitochondrial membrane potential was improved and Cyt c release into the cytoplasm was prevented which led to significantly suppressed up-regulation of Bax reducing the Bax/Bcl-2 ratio. The expressions of caspase-3 and caspase-9 induced by high glucose exposure were also ameliorated in the RGCs treated with EPO. The protective effect of EPO against apoptosis was mediated through its antioxidant action. Thus, it blocked the generation of pro-apoptotic proteins and apoptotic degeneration of the RGCs by preventing the mitochondrial damage.
- Open Access
- 15 April 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (8) , 951-961
Regulation of SCFSKP2 Ubiquitin E3 Ligase Assembly and p27KIP1 Proteolysis by the PTEN Pathway and Cyclin D1
The PTEN tumor suppressor functions as a phosphatase of phosphatidylinositol 3,4,5-trisphosphate (PIP3) and negatively regulates the PI 3-kinase signaling pathway. Our previous studies showed that PTEN expression causes accumulation of cyclin-dependent kinase inhibitor p27Kip1 and G1 cell cycle arrest. Here, we show that PTEN negatively regulates expression of cyclin D1 and that cyclin D1 plays a unique role in p27 proteolysis. Co-expression of cyclin D1, but not cyclin E, is sufficient to restore p27 levels in PTEN-expressing cells. Conversely, loss of cyclin D1 by siRNA causes p27 accumulation. Silencing of the cyclin D1 gene or inhibition of the PI 3-kinase pathway prevents formation of the SCFSKP2 complex, with a simultaneous increase in CUL1 binding to CAND1. CAND1-CUL1 binding is known to block the accessibility of CUL1 to SKP1 and SKP2. We have found that CUL1 is less neddylated in cells that have lost cyclin D1 expression. Using an in vitro extract system, we found that the extracts prepared from cells lacking cyclin D1 have reduced activity to neddylate CUL1, in a manner similar to extracts from cells treated with a PI 3-kinase inhibitor or in G0 resting cells. Consistenly, the steady state levels of CUL1 neddylation were found lower under these conditions. Our studies reveal that PTEN/PI 3-kinase signaling and cyclin D1 control a novel pathway that regulates assembly of the SCFSKP2 complex by modulating cullin neddylation and CAND1 binding at the G1/S cell cycle transition.
- 15 April 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (8) , 951-961
Open AccessRegulation of SCFSKP2 Ubiquitin E3 Ligase Assembly and p27KIP1 Proteolysis by the PTEN Pathway and Cyclin D1
The PTEN tumor suppressor functions as a phosphatase of phosphatidylinositol 3,4,5-trisphosphate (PIP3) and negatively regulates the PI 3-kinase signaling pathway. Our previous studies showed that PTEN expression causes accumulation of cyclin-dependent kinase inhibitor p27Kip1 and G1 cell cycle arrest. Here, we show that PTEN negatively regulates expression of cyclin D1 and that cyclin D1 plays a unique role in p27 proteolysis. Co-expression of cyclin D1, but not cyclin E, is sufficient to restore p27 levels in PTEN-expressing cells. Conversely, loss of cyclin D1 by siRNA causes p27 accumulation. Silencing of the cyclin D1 gene or inhibition of the PI 3-kinase pathway prevents formation of the SCFSKP2 complex, with a simultaneous increase in CUL1 binding to CAND1. CAND1-CUL1 binding is known to block the accessibility of CUL1 to SKP1 and SKP2. We have found that CUL1 is less neddylated in cells that have lost cyclin D1 expression. Using an in vitro extract system, we found that the extracts prepared from cells lacking cyclin D1 have reduced activity to neddylate CUL1, in a manner similar to extracts from cells treated with a PI 3-kinase inhibitor or in G0 resting cells. Consistenly, the steady state levels of CUL1 neddylation were found lower under these conditions. Our studies reveal that PTEN/PI 3-kinase signaling and cyclin D1 control a novel pathway that regulates assembly of the SCFSKP2 complex by modulating cullin neddylation and CAND1 binding at the G1/S cell cycle transition.